News
Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.
The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% ...
2d
Investor's Business Daily on MSNThe FDA Will Reportedly Ask Sarepta To Stop Selling Elevidys. Shares Plummet.Sarepta stock crashed Friday on reports the FDA will ask the biotech company to stop shipments of its approved gene therapy, ...
Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...
US stocks rose on Monday, with fresh records for the Nasdaq Composite (^IXIC) and S&P 500 (^GSPC) in sight as Wall Street ...
What happenedShares of Sarepta Therapeutics (NASDAQ: SRPT) were crashing 50.7% as of 11:11 a.m. EST on Friday. The huge decline came after the biotech announced top-line results late on Thursday ...
Sarepta Therapeutics, a company that develops RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, has seen its stock decline by 54% year-to-date. The decline is due ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results